Evidence map›Paper›PMID 41771582›Full record

Trial reportInternational wound journal2026

Intent to Treat Analysis of the Primary and Secondary Outcomes for the ODINN Intact Fish Skin Graft for Deep Diabetic Foot Wounds Trial.

Dured Dardari, Alberto Piaggesi, Louis Potier, Ariane Sultan, Holger Diener, Maud Francois, Bernhard Dorweiler, Benjamin Bouillet, Jocelyne M'Bemba, Lucy Chaillous and 10 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Dured DardariDiabetology Department, Center Hopitalier Sud Francilien, Corbeil-Essonnes, France.
Alberto PiaggesiDiabetic Foot Section, Department of Endocrinology and Metabolism, University Hospital Pisa, Pisa, Italy.
Louis PotierDiabetology Department, CHU Bichat-Claude Bernard, AP-HP, Paris, France.
Ariane SultanDiabetology Nutrition Department, CHU Montpelier, Université de Montpellier, Montpellier, France.
Holger DienerDepartment of Vascular and Endovascular Surgery, Wound Competence Center, Krankenhaus Bucholz, Buchholz, Germany.
Maud FrancoisDiabetology Department, CHU de Reims Hôpital Robert Debré, Reims, France.
Bernhard DorweilerDepartment of Vascular and Endovascular Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Benjamin BouilletDepartment of Endocrinology-Diabetology, CHU de Dijon, Dijon University Hospital, Dijon, France.
Jocelyne M'BembaDepartment of Diabetology, CHU Cochin, Hôpital Cochin, Paris, France.
Lucy ChaillousDepartment of Endocrinology-Diabetology-Nutrition, L'institut du Thorax, CHU de Nantes, University Hospital of Nante, Nantes, France.
Giacomo ClericiSan Carlo Hospital, Paderno-Dugnano, Italy.
Laurence KesslerDepartment of Diabetology, CHU de Strasbourg - Hôpital Civil, Strasbourg, France.
Walter Wetzel-RothBelegarzt Wertachkliniken, Munich, Germany.
Martin StorckStädtisches Klinikum Karlsruhe, Karlsruhe, Germany.
Dereck ShiIndependent Cosultant, Minneapolis, Minnesota, USA.
Olafur DavidssonIndependent Cosultant, Minneapolis, Minnesota, USA.
Baldur BaldurssonLandspitali University Hospital, Reykjavík, Iceland.
Hilmar KjartanssonLandspitali University Hospital, Reykjavík, Iceland.
Guillaume CharpentierCERITD (Center for Study and Research for Improvement of the Treatment of Diabetes), Bioparc-Genopole Evry-Corbeil, Evry, France.
John C LantisMount Sinai West Hospital, Icahn School of Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0002-3615-6512

Funding

Horizon 2020 research and innovation program 878896Kerecis LLC, Reykjavik IS
6 · The paper itself

Abstract

There is a significant need for trials that evaluate the treatment of University of Texas (UT) grade 2 and 3 diabetic foot ulcers (bone, joint, or tendon exposed wounds). We undertook a trial looking at the effect of intact fish skin graft (IFSG) on these deep and difficult-to-heal ulcers. 262 patients Intent to Treat (ITT) patients with UT grade 2 and 3 DFUs were randomised to receive intact fish skin graft (IFSG) or a standardised treatment (SOC) that adhered to the International Working Group on the Diabetic Foot (IWGDF) guidelines. The secondary endpoints that were measured included wound area reduction (WAR), healing rates at 20 and 24 weeks; closure rates by UT grade, perfusion, quality of life, pain reduction and IFSG safety. We report ITT (all randomised) (mITT previosly reported) The (WAR) at 12 weeks was 65.53% for IFSG versus 30.82% for SOC (p = 0.007). UT 2 wounds (60% of total) exhibited a closure rate of 47% versus 23% at 16 weeks for IFSG versus SOC (p = 0.0033). Target wound infections were comparable (39 vs. 37) and major outcomes were comparable during the 24 week period (target-limb amputations 8% vs. 7%). Time-to-heal favoured IFSG (restricted mean to 24 weeks 17.31 vs. 19.37 weeks; KM/log-rank significant; Cox HR 1.59). The in the treatment of deep complex diabetic foot wounds the addition of IFSG significantly improved the number of patients with total wound closure as well as the time to wound closure without increased risk of complications. This improvement in total wound closure and time to wound closure was noted across prior amputation status, quality of perfusion, and UT grade.

Indexed as

Diabetic FootSkin TransplantationWound HealingAgedAnimalsFemaleFishesHumansIntention to Treat AnalysisMaleMiddle AgedTreatment Outcome

Identifiers

PMID41771582
PMCPMC12952979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.